Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Disease × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Disease 1

Interventions

Magnetic Resonance Spectroscopy 6 Dexamethasone 6 Cyclophosphamide 6 Blood Specimen Collection 6 Prednisone 5 Positron Emission Tomography Computed Tomography 4 Mammography 4 Lenalidomide 4 Colonoscopy 4 pembrolizumab 3 Tomography, X-Ray Computed 3 Surveys and Questionnaires 3 Melphalan 3 Biopsy 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 weifuchun 2 obinutuzumab 2 fluciclovine F-18 2 daratumumab 2 carfilzomib 2 Preoperative Exercise 2 Positron-Emission Tomography 2 Methods 2 Magnetic Resonance Imaging 2 Injections 2 Gemcitabine 2 Exercise 2 Educational Status 2 Doxorubicin 2 Cytarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡